Rein Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Rein Therapeutics, Inc. (RNTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.10% for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-14
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-09-30 was 3.70%.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.30%, a 84.55% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 2.33%, a 0.00% change year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-03-31 was 2.33%, a 237.68% increase year-over-year.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.00%, a 2.44% decline from fiscal 2024.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.10%, a 16.33% decline from fiscal 2023.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.90%, a 96.00% increase from fiscal 2022.
- Rein Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.50%, a 160.42% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 4.10% 10-Q · filed 2026-08-14 | ||||||
| 2025-12-31 | 4.00% 10-K · filed 2026-03-26 | ||||||
| 2025-09-30 | 4.00% 10-Q · filed 2025-11-14 | ||||||
| 2025-06-30 | 4.30% 10-Q · filed 2025-08-14 | ||||||
| 2024-12-31 | 4.10% 10-K · filed 2026-03-26 | ||||||
| 2024-09-30 | 3.70% 10-Q · filed 2024-11-14 | 3.70% 10-Q · filed 2025-11-14 | 4.30% 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | 4.30% 10-Q · filed 2024-08-14 | ||||||
| 2024-03-31 | 4.30% 10-Q · filed 2025-05-15 | 4.26% 10-Q · filed 2024-05-15 | |||||
| 2023-12-31 | 4.90% 10-K · filed 2025-04-07 | ||||||
| 2023-09-30 | 2.46% 10-Q · filed 2023-10-13 | ||||||
| 2023-06-30 | 2.46% 10-Q · filed 2023-08-11 | ||||||
| 2023-03-31 | 2.33% 10-Q · filed 2024-05-15 | ||||||
| 2022-12-31 | 2.50% 10-K · filed 2024-04-15 | ||||||
| 2022-09-30 | 2.46% 10-Q · filed 2022-11-01 | ||||||
| 2022-06-30 | 2.46% 10-Q · filed 2022-08-15 | ||||||
| 2022-03-31 | 2.33% 10-Q · filed 2023-05-08 | ||||||
| 2021-12-31 | 0.96% 10-K · filed 2023-03-20 | ||||||
| 2021-09-30 | 0.96% 10-Q · filed 2022-11-01 | ||||||
| 2021-06-30 | 0.96% 10-Q · filed 2022-08-15 | ||||||
| 2021-03-31 | 0.69% 10-Q · filed 2022-05-05 | ||||||
| 2020-12-31 | 1.17% 10-K · filed 2022-03-28 | ||||||
| 2020-09-30 | 1.19% 10-Q · filed 2021-11-12 | ||||||
| 2020-06-30 | 1.03% 10-Q · filed 2021-08-11 | ||||||
| 2020-03-31 | 1.29% 10-Q · filed 2021-05-11 | ||||||
| 2019-12-31 | 2.35% 10-K · filed 2021-03-24 | ||||||
| 2019-09-30 | 2.35% 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | 2.53% 10-Q · filed 2020-08-05 | 2.35% 10-Q · filed 2019-08-06 | |||||
| 2019-03-31 | 2.53% 10-Q · filed 2020-05-11 | ||||||
| 2018-12-31 | 2.93% 10-K · filed 2020-03-30 | ||||||
| 2018-09-30 | 2.77% 10-Q · filed 2019-11-07 | ||||||
| 2018-06-30 | 2.75% 10-Q · filed 2019-08-06 | ||||||
| 2018-03-31 | 2.67% 10-Q · filed 2019-05-08 | ||||||
| 2017-12-31 | 2.16% 10-K · filed 2019-03-29 | ||||||
| 2017-09-30 | 2.15% 10-Q · filed 2018-11-07 | ||||||
| 2017-06-30 | 2.19% 10-Q · filed 2018-08-07 | ||||||
| 2017-03-31 | 2.31% 10-Q · filed 2018-05-09 | ||||||
| 2016-12-31 | 1.37% 10-K · filed 2018-04-02 | ||||||
| 2016-09-30 | 1.37% 10-Q · filed 2017-11-09 | ||||||
| 2016-06-30 | 1.37% 10-Q · filed 2017-08-10 | ||||||
| 2015-12-31 | 2.01% 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |